Trethera
  • Home
  • About Us
  • Technology
  • Pipeline
  • Media
    • News
    • Publications
  • Contact
  • Menu

News

Trethera Scientific Founder Dr. Caius Radu To Present Research At Los Angeles Bioscience Ecosystem Summit 2022

19th May 2022/in News /by Trethera

Los Angeles, May 19, 2022 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces a forthcoming presentation by scientific founder Dr. Caius Radu at the Los Angeles Bioscience Ecosystem Summit 2022 (“LABEST”). Presentation Details: Title: Development of a […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2022-05-19 22:14:542022-05-19 23:39:49Trethera Scientific Founder Dr. Caius Radu To Present Research At Los Angeles Bioscience Ecosystem Summit 2022

Trethera Announces Completion of $3.8 Million Seed Funding Round From Current Investors

13th May 2022/in News /by Trethera

Los Angeles, May 11, 2022 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces the completion of a follow-on seed financing of $3.8 million from its existing investors.  Funds will be used for working capital purposes. “This capital […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2022-05-13 00:43:202022-05-13 00:44:58Trethera Announces Completion of $3.8 Million Seed Funding Round From Current Investors

Trethera Announces Prostate Cancer Poster Presentation at the American Association for Cancer Research Annual Meeting

22nd March 2022/in News /by Trethera

Los Angeles, March 22, 2022 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting.  Dr. Caius Radu, of the University of California Los Angeles, […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2022-03-22 19:54:032022-03-23 14:40:48Trethera Announces Prostate Cancer Poster Presentation at the American Association for Cancer Research Annual Meeting

Safety Review Committee Advances Trethera Phase 1 Solid Tumors Trial to Next Dose After First Patient Cohort Achieves Primary Endpoint

14th December 2021/in News /by Trethera

Los Angeles, December 9, 2021— Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the first patient cohort completed their full dose cycle with no serious adverse events (SAEs) in its multi-site Phase 1 oncology trial. The safety and tolerability of TRE-515, a first-in-class drug targeting the enzyme deoxycytidine kinase (dCK) […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2021-12-14 16:28:032021-12-14 16:49:27Safety Review Committee Advances Trethera Phase 1 Solid Tumors Trial to Next Dose After First Patient Cohort Achieves Primary Endpoint

Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 for the Treatment of Demyelinating Optic Neuritis

15th November 2021/in News /by Trethera

Los Angeles, November 12, 2021— Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status (ODS) to TRE-515 for the treatment of optic neuritis (ON). ON is a rare autoimmune disease where patients rapidly lose vision in one or both eyes with 1 in 10 patients never fully recovering their eyesight. TRE-515 is a first-in-class drug targeting the enzyme deoxycytidine kinase (dCK). […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2021-11-15 03:37:462021-12-14 16:50:58Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 for the Treatment of Demyelinating Optic Neuritis
Page 3 of 512345